CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as the absence of cell surface receptors renders it more difficult to be therapeutically targeted. Chemokine receptor 2 (CXCR2) has been suggested not only to promote therapy resistance and suppress immunotherapy but...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghallab, Alaa M., Eissa, Reda A., El Tayebi, Hend M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065340/
https://www.ncbi.nlm.nih.gov/pubmed/35517812
http://dx.doi.org/10.3389/fphar.2022.862125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065340/
https://www.ncbi.nlm.nih.gov/pubmed/35517812
http://dx.doi.org/10.3389/fphar.2022.862125

Ejemplares similares